CancerDrs

Leukemia clinical trials in Indiana

23 actively recruiting leukemia trials at 8 sites across Indiana.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full leukemia transparency page →

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Indiana:
  • UChicago Medicine Northwest Indiana — Crown Point, Indiana
  • Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
  • Reid Health — Richmond, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Indiana:
  • Riley Hospital for Children — Indianapolis, Indiana
  • Ascension Saint Vincent Indianapolis Hospital — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olverembatinib (HQP1351) in Patients With CML-CP

Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T…

Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06423911
Sites in Indiana:
  • Ascentage Investigative Site #1069 — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…

Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Indiana:
  • Indiana University School of Medicine — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…

Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Indiana:
  • Northwest Cancer Center - Dyer Clinic /ID# 268478 — Dyer, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in Indiana:
  • Fort Wayne Medical Oncology and Hematology ( Site 5444) — Fort Wayne, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (C…

Sponsor: CSL Behring
NCT ID: NCT07648264
Sites in Indiana:
  • Indiana University Health Arnett, Inc. — Lafayette, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Indiana:
  • Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Indiana:
  • Riley Hospital for Children — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Indiana:
  • UChicago Medicine Northwest Indiana — Crown Point, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younge…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06672146
Sites in Indiana:
  • UChicago Medicine Northwest Indiana — Crown Point, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibito…

Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT07221500
Sites in Indiana:
  • Fort Wayne Oncology and Hematology — Fort Wayne, Indiana
  • Hematology Oncology of Indiana — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…

Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in Indiana:
  • Riley Hospital for Children - Indiana University — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be c…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04925479
Sites in Indiana:
  • Indiana UH Riley H for CIU — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may sto…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06484062
Sites in Indiana:
  • UChicago Medicine Northwest Indiana — Crown Point, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Network

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic…

Sponsor: Children's Oncology Group
NCT ID: NCT06247787
Sites in Indiana:
  • Riley Hospital for Children — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolesce…

Sponsor: New York Medical College
NCT ID: NCT04972942
Sites in Indiana:
  • Riley Children's Hospital — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

ALT-101 is a first-in-human Phase 1 clinical trial testing a new antibody drug called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. 4A10 is a targeted therapy designed to reco…

Sponsor: Allterum Therapeutics, Inc
NCT ID: NCT07586618
Sites in Indiana:
  • Riley Children's Hosptial — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

CD4CAR for CD4+ Leukemia and Lymphoma

This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the…

Sponsor: Huda Salman
NCT ID: NCT03829540
Sites in Indiana:
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
  • Riley Hospital for Children — Indianapolis, Indiana
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Indiana:
  • Parkview Research Center — Fort Wayne, Indiana
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukem…

Sponsor: Massachusetts General Hospital
NCT ID: NCT05237258
Sites in Indiana:
  • Indiana University — Bloomington, Indiana
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01